{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:58:22Z","timestamp":1761325102426,"version":"build-2065373602"},"reference-count":3,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,10,15]]},"abstract":"<jats:p>\n                    This news section offers\n                    <jats:italic>Cancer<\/jats:italic>\n                    readers timely information on events, public policy analysis, and topical issues. In this issue, CAR T\u2010cell therapy shows impressive outcomes for patients with refractory multiple myeloma. In addition, an analysis of real\u2010world evidence on the use of comprehensive genomic profiling in patients with metastatic cancer showed its effectiveness in matching targeted therapy, and low\u2010dose olanzapine is effective and safe for preventing chemotherapy\u2010induced nausea and vomiting.\n                  <\/jats:p>","DOI":"10.1002\/cncr.70057","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:00:56Z","timestamp":1760698856000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T\u2010cell therapy shows impressive outcomes for patients with refractory multiple myeloma"],"prefix":"10.1002","volume":"131","author":[{"given":"Mary Beth","family":"Nierengarten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:53:48Z","timestamp":1761324828000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70057"}},"subtitle":["One third of patients did not need maintenance or subsequent treatment and presented without disease progression at 5 years and beyond."],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":3,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,15]]}},"alternative-id":["10.1002\/cncr.70057"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70057","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"2025-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70057"}}